Introduction

In Search of Stakeholder Collaboration to Stem the Cardiometabolic Epidemic

Dalia Buffery, MA, ABD

Original Research

Obesity in the Workplace: Impact on Cardiovascular Disease, Cost, and Utilization of Care

Alberto M. Colombi, MD, MPH; G. Craig Wood, MS
Stakeholder Perspective by Wayne M. Lednar, MD, PhD

Clinical

A Call to Action: Responding to the Future Forecasting of Cardiovascular Disease in America

Robert Lee Page ii, PharmD, MSPH, FAHA, FCCP, FASCcP, FASHP, BCPS; Vahram Ghushchyan, PhD; Kavita Nair, PhD
Stakeholder Perspective by James T. Kenney, RPh, MBA

Atypical Antipsychotics and Metabolic Syndrome in Patients with Schizophrenia: Risk Factors, Monitoring, and Healthcare Implications

Henry J. Riordan, PhD; Paola Antonini, MD, PhD; Michael F. Murphy, MD, PhD
Stakeholder Perspective by Atheer A. Kaddis, PharmD

Current Therapies and Emerging Drugs in the Pipeline for Type 2 Diabetes

Quang T. Nguyen, DO; Karmella T. Thomas, BS, RD; Katie B. Lyons, MS II; Loida D. Nguyen, PharmD, BCBS; Raymond A. Plodkowski, MD
Stakeholder Perspective by James V. Felicetta, MD

Lipid Management in Patients with Type 2 Diabetes

Marsha J. Daniel, PharmD, cPh, CDE
Stakeholder Perspective by Gary M. Owens, MD